日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Correction: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

更正:通过三重阻断 mTORC1、表皮生长因子和雌激素受体信号通路来靶向内分泌耐药性乳腺癌的肿瘤重编程

Ribas, Ricardo; Pancholi, Sunil; Rani, Aradhana; Schuster, Eugene; Guest, Stephanie K; Nikitorowicz-Buniak, Joanna; Simigdala, Nikiana; Thornhill, Allan; Avogadri-Connors, Francesca; Cutler, Richard E Jr; Lalani, Alshad S; Dowsett, Mitch; Johnston, Stephen R; Martin, Lesley-Ann

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

更正:HDAC抑制剂可增强奈拉替尼的活性,并且当与奈拉替尼联合使用时,可增强抗PD-1免疫调节抗体在体内的作用。

Booth, Laurence; Roberts, Jane L; Poklepovic, Andrew; Avogadri-Connors, Francesca; Cutler, Richard E; Lalani, Alshad S; Dent, Paul

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib

不可逆的ERBB1/2/4抑制剂奈拉替尼以Beclin1/ATG5依赖的方式迅速降低突变型K-RAS和突变型N-RAS的水平。

Booth, Laurence; Roberts, Jane L; Poklepovic, Andrew; Kirkwood, John; Sander, Cindy; Avogadri-Connors, Francesca; Cutler, Richard E Jr; Lalani, Alshad S; Dent, Paul

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration

[奈拉替尼+丙戊酸盐]联合治疗可永久性降低4T1乳腺肿瘤中ERBB1和RAS的表达,并增强M1型巨噬细胞的浸润。

Booth, Laurence; Roberts, Jane L; Rais, Rumeesa; Kirkwood, John; Avogadri-Connors, Francesca; Cutler, Richard E Jr; Lalani, Alshad S; Poklepovic, Andrew; Dent, Paul

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

HDAC 抑制剂可增强奈拉替尼的活性,并且当与抗 PD-1 免疫调节抗体联合使用时,可增强其在体内的作用

Booth Laurence, Roberts Jane L, Poklepovic Andrew, Avogadri-Connors Francesca, Cutler Richard E, Lalani Alshad S, Dent Paul